trending Market Intelligence /marketintelligence/en/news-insights/trending/aAzpJvn2x3KOesgChhGqrw2 content esgSubNav
In This List

Achillion drug secures second US FDA orphan drug designation

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Achillion drug secures second US FDA orphan drug designation

Achillion Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's orphan drug designation for ACH-4471 to treat a rare, kidney-related disease known as C3 Glomerulopathy.

ACH-4471 previously received the U.S. FDA's orphan drug designation to treat paroxysmal nocturnal hemoglobinuria that is characterized by red blood cell destruction, blood clots and impaired bone marrow function.